Drug Trial Radar · NCT07328542
Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men
Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Feb 2026
Primary completion
Jun 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Azurity PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- CBCC Global Research
- First posted
- Jan 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 4, multi-center, open-label, single-arm 24-hour Ambulatory Blood Pressure Monitoring (ABPM) study of Testosterone Cypionate Injection in Hypogonadal Men to assess change in 24-hour ambulatory blood pressure from Baseline to End of Treatment
Conditions
- Hypogonadism, Male
Interventions
Testosterone Cypionate Injection 200 mg/mLDrug
Participants will receive Testosterone Cypionate Injection 200 mg/mL at established dose during the titration and treatment periods every two weeks (± 2 days) as a deep intramuscular injection in the gluteal muscle for 14-week study duration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with changes in 24-hour average systolic ambulatory blood pressureTime frame: From Baseline to End of Treatment, up to Week 14 (Day 99)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Alabama Clinical Therapeutics, LLC
Birmingham, Alabama
Hillcrest Medical Research, LLC
DeLand, Florida
Integrity Clinical Research Center, Inc.
Hialeah, Florida
AccuMed Research Associates
Garden City, New York
Aim Trials
Plano, Texas
Alpine Clinical Organization Inc.
Clinton, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.